

March 16, 2020

Attention: To the Physicians and Office Staff involved in the care of women diagnosed with DCIS

During these unprecedented times PreludeDx will remain open and continue processing tests in our laboratory. We know that the DCISionRT results assist you in providing critical information for patient navigation and shared treatment decision-making.

While PreludeDx will continue operations, we will be following the CDC recommended guidelines to ensure the safety of our personnel and we have implemented additional workplace precautions to minimize any potential exposure to the COVID-19 virus. We recognize that our employees are the backbone of our company and they will continue to serve you and your patients.

We have instructed our non-patient critical work teams to work remotely and we are still committed to providing you our normal 3-5-day test turn-around time. Our Customer Care Representatives will remain available to answer any questions about specimen results or overall operations.

While the normal process of treating your patients continues to change daily, please know DCISionRT testing remains available to assist in treatment decision-making. Our field representatives are standing by and are available by phone, webcast and in person if needed. For the time being, we are trying to limit personal contact and minimize the spread of COVID-19.

We understand that cancer does not stop during a national crisis and our commitment to you and your patients remains steady and resolute. Our concern is for the health and safety of our employees and their families, you and your staff, and of paramount concern, the women we both serve.

If you have any questions, please contact Customer Care at **888 211 DCIS (3247)**.

In good health,



Daniel Forche
President and CEO
PreludeDx